Microbot Medical Inc当前公司基本面数据相对谨慎,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名152/404位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价8.75。中期看,股价处于下降通道。近一个月,市场表现较强,技术面评分较高,但较强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。
Microbot Medical Inc评分
相关信息
行业排名
152 / 404
全市场排名
280 / 4582
所属行业
生物技术与医疗研究
压力支撑
由于公司未披露,未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
2
位分析师
买入
评级
8.750
目标均价
+270.76%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议
Microbot Medical Inc亮点
亮点风险
Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.
Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.
公司代码MBOT
公司Microbot Medical Inc
CEOGadot (Harel)
网址http://www.microbotmedical.com/
常见问题
Microbot Medical Inc(MBOT)的当前股价是多少?
Microbot Medical Inc(MBOT)的当前股价是 2.210。
Microbot Medical Inc的股票代码是什么?
Microbot Medical Inc的股票代码是MBOT。
Microbot Medical Inc股票的52周最高点是多少?
Microbot Medical Inc股票的52周最高点是4.670。
Microbot Medical Inc股票的52周最低点是多少?
Microbot Medical Inc股票的52周最低点是0.960。
Microbot Medical Inc的市值是多少?
Microbot Medical Inc的市值是145.49M。
Microbot Medical Inc的净利润是多少?
Microbot Medical Inc的净利润为-11.44M。
现在Microbot Medical Inc(MBOT)的股票是买入、持有还是卖出?
根据分析师评级,Microbot Medical Inc(MBOT)的总体评级为买入,目标价格为8.750。
Microbot Medical Inc(MBOT)股票的每股收益(EPS TTM)是多少
Microbot Medical Inc(MBOT)股票的每股收益(EPS TTM)是-0.450。